Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2024Nephrology Dialysis TransplantationOpen Access

#1491 Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

View Full Paper
Ask AI
Bookmark
Share

Authors

LKLucas KühneUniversity of ColognePKPaul KnöblRoyal London HospitalKEKathrin EllerUniversity of Graz

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kühne et al. (2024) studied this question.

synapsesocial.com/papers/68e6c494b6db643587642afchttps://doi.org/10.1093/ndt/gfae069.117
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effectiveness of caplacizumab in the first-line treatment for acquired thrombotic thrombocytopenic purpura: single center experience2026
  2. 2Personalised treatment of patients with immune thrombotic thrombocytopenic purpura2025
  3. 3Real-World Data Analysis of Patients Affected by Immune-Mediated Thrombotic Thrombocytopenic Purpura in Italy2024 · 5 citations
  4. 4IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: PATHOPHYSIOLOGY, DIAGNOSIS AND OPEN ISSUES.2024 · 5 citations
  5. 5A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA : A Multicenter Study of 390 Disease Episodes From 2017 to 20212025 · 3 citations